EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina


A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina



New England Journal of Medicine 338(21): 1498-1505



ISSN/ISBN: 0028-4793

Background. Activation of platelets is central to the pathophysiology of unstable angina. We studied whether inhibition of the final common pathway for platelet aggregation with tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, would improve clinical outcome in this condition. Methods. In a double-blind study, we randomly assigned 3232 patients who were already receiving aspirin to additional treatment with intravenous tirofiban or heparin for 48 hours. The primary end point was a composite of death, myocardial infarction, or refractory ischemia at 48 hours. Results. The incidence of the composite end point was 32 percent lower at 48 hours in the group that received tirofiban (3.8 percent, vs. 5.6 percent with heparin; risk ratio, 0.67; 95 percent confidence interval, 0.48 to 0.92; P=0.01). Percutaneous revascularization was performed in 1.9 percent of the patients during the first 48 hours. At 30 days, the frequency of the composite end point (with the addition of readmission for unstable angina) was similar in the two groups (15.9 percent in the tirofiban group vs. 17.1 percent in the heparin group, P=0.34). There was a trend toward a reduction in the rate of death or myocardial infarction with tirofiban (a rate of 5.8 percent, as compared with 7.1 percent in the heparin group; risk ratio, 0.80; 95 percent confidence interval, 0.61 to 1.05; P=0.11), and mortality was 2.3 percent, as compared with 3.6 percent in the heparin group (P=0.02). Major bleeding occurred in 0.4 percent of the patients in both groups. Reversible thrombocytopenia occurred more frequently with tirofiban than with heparin (1.1 percent vs. 0.4 percent, P=0.04). Conclusions. Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed. The incidence of refractory ischemia and myocardial infarction was not reduced at 30 days, but mortality was lower among the patients given tirofiban. Platelet inhibition with aspirin plus tirofiban may have a role in the management of unstable angina.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008030737

Download citation: RISBibTeXText

Related references

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New England journal of medicine 338(21): 1498-1505, 1998

Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. Journal of the American College of Cardiology 24(1): 39-45, 1994

Tirofiban combined with heparin and aspirin prevented ischemic events in patients with unstable angina and non-Q-wave MI. Evidence-Based Cardiovascular Medicine 2(4): 104-105, 1998

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 345(8959): 1201-1204, 1995

Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA 276(23): 1873; Author Reply 1874, 1996

Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA 276(23): 1873; Author Reply 1874, 1996

Benefit of heparin plus aspirin vs aspirin alone in unstable angina. JAMA 276(23): 1873-4; author reply 1874, 1996

Does combined aspirin with heparin or aspirin with enoxaparin therapy versus aspirin alone therapy reduce cardiac events in patients with unstable angina pectoris? Study performed in 201 patients. European Heart Journal 18(ABSTR Suppl. ): 129, 1997

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet (North American Edition) 345(8959): 1201-1204, 1995

Tirofiban plus aspirin reduced ischemic events in patients with unstable angina. Evidence-Based Cardiovascular Medicine 2(4): 104-105, 1998

Reduction of recurrent angina and silent ischaemia in patients with unstable angina A pilot study using low molecular weight heparin, heparin or aspirin. European Heart Journal 15(ABSTR Suppl. ): 545, 1994

Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. European Heart Journal 15(9): 1196-1203, 1994

Heparin plus aspirin for unstable angina. Emergency nurse: the journal of the RCN Accident and Emergency Nursing Association 4(4): 27, 1997

Low-molecular heparin Sulodexide vs heparin plus aspirin in unstable angina pectoris. Cardiovascular Drugs and Therapy 7(Suppl. 2): 462, 1993

Low molecular weight heparin, regular heparin or aspirin to treat silent ischemia in unstable angina. Journal of the American College of Cardiology 1995(SPEC ISSUE): 420A, 1995